View Now | C-Path in Europe: Moving Global Regulatory Science Forward
In support of C-Path’s mission to catalyze innovation that accelerates the path to a healthier world, we’re excited to invite you to this webinar to learn more about how C-Path’s new headquarters in Amsterdam will continue to improve public health, share expertise, data, risks and costs to move global regulatory science forward by facilitating public-private partnerships with members from the biopharmaceutical industry, government regulatory agencies, academic institutions, and patient groups in Europe.
Speakers include C-Path scientific leadership who will present on-going activities on key topics, including:
- Digital Technologies
- Real-World Evidence
- Model Informed Drug Development
- Complex Clinical Trials
Following presentations, audience questions will be answered by a panel of representatives from EFPIA, academia, EMA and patient groups.
| Topic | Speaker |
|---|---|
| Welcome and Introduction | Kristen Swingle Tomas Salmonson |
| C-Path global vision and mission | Klaus Romero |
| EMA Regulatory Science Strategy (RSS) & How C-Path Can Contribute | Cecile Ollivier |
| Drug Development Tools | Klaus Romero |
| Complex Clinical Trials and Digital Technologies | Terina Martinez Martijn Muller |
| Patient-Centric Drug Development and Real-world Evidence | Scottie Kern Jeff Barrett |
| Repurposed Drugs | Marco Schito |
| Collaborations and Training in Regulatory Science | Jeff Barrett Huong Huynh |
| Q&A for C-Path Speakers | C-Path Speakers |
| Panel Discussion (industry, academia, regulators, patient groups) | Lada Leyens Ralf Herold Dimitrios Athanasiou Franz Koenig |
| Closing remarks | Cecile Ollivier |
C-Path Speakers
- Kristen Swingle: Interim President & Chief Operating Officer (US)
- Tomas Salmonson: Member, Board of Directors (US) & Member, Board of Directors (Netherlands)
- Klaus Romero: Chief Science Officer & Executive Director of Clinical Pharmacology (US)
- Cecile Ollivier: EU Regulatory Science Advisor (US) & Member, Board of Directors (Netherlands)
- Terina Martinez: Executive Director Duchenne Regulatory Science Consortium & Critical Path to Therapeutics for the Ataxias (US)
- Martijn Muller: Senior Scientific Director, Critical Path for Parkinson’s Consortium (US)
- Scottie Kern: Executive Director, Electronic Clinical Outcome Assessment Consortium (US)
- Jeff Barrett: Senior Vice President; Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) Lead (US)
- Huong Huynh: Director, Regulatory Science (US)
Panelists
- Lada Leyens: Global Regulatory Lead, Clinical Trial Innovation & Digital Health at Roche
- Ralf Herold: Senior Scientific Officer, Taskforce Regulatory Science & Innovation at EMA
- Dimitrios Athanasiou: PDCO Member at EMA – EURORDIS Board, Member in World Duchenne Organization, European Patients Forum Greek Patient Association
- Franz Koenig: Associate Professor, Medical University of Vienna
To learn more about C-Path in Europe, visit https://c-path.org/c-path-in-europe/ and read C-Path European Nonprofit Established in Amsterdam.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
